Bildkälla: Stockfoto

Cantargia: Nadunolimab Ready for Phase II in PDAC - Redeye

Redeye comments on the FDA approval to start a randomized phase IIb study with nadunolimab in pancreatic cancer.

Redeye comments on the FDA approval to start a randomized phase IIb study with nadunolimab in pancreatic cancer.
Börsvärldens nyhetsbrev
ANNONSER